• ABPI Website
  • Media
  • ABPI response to £210 million DHSC antimicrobial awareness funding

ABPI response to £210 million DHSC antimicrobial awareness funding

The Department of Health and Social Care has announced £210 million worth of funding as part of the Fleming Fund’s activities to tackle AMR in countries across Asia and Africa over the next three years.

Claire Machin, ABPI Executive Director, International Policy & UK Competitiveness said: “In the face of the daunting challenge posed by antimicrobial resistance, continued funding into this global issue remains a key priority. Advancing research, surveillance, and international collaboration on innovative solutions to combat AMR through a One Health approach is essential.

“The pharmaceutical industry has also stepped up support and invested £1.2 billion to bring new antibiotics to market by 2030 through the AMR Action Fund. Commitments from both our industry and policymakers worldwide mean we can counteract the threat of AMR and secure the well-being of generations to come."

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.